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 Abstract 
 
The theoretical case is considered where the total amount of plasma protein is conserved, but the 
drug is eliminated after its single application.  
After a single drug application at time t = 0, the total drug concentration is measured at times ti,…,tk 
and the total drug concentration at time ti is denoted by φi. 
 Our discussion is limited to one protein binding site. The quantity of plasma protein (Λ), the 
association constant (Ka) and the total concentration of the drug φi at time ti are considered as 
independent variables. 
 Free drug concentration, plasma protein bound concentration and free drug fraction are 
given as functions of these ”new” variables. The aim of this communication is to derive the formula  
that allows to calculate the free drug concentration at any time after the drug application, based on 3 
parameters: the association constant of the drug, the total plasma concentration of the drug and the 
concentration of the protein. 
If the plasma protein quantity (Λ) and the association constant (Ka) are known, then from the 
knowledge of the total drug concentration φi at time ti it is possible to determine the free drug 
concentration at time ti. 
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Introduction 
 
 Pharmacological effect of a drug over time is the result of pharmacokinetic and 
pharmacodynamic processes determined by concentration of a free, non-protein bound form of the 
drug in the vascular bed. In experiments, the total concentration of a drug is usually determined as a 
sum of the free concentration of a drug (cfree) and plasma protein bound concentration (cbound)(1).  
 The total drug concentration φ is a sum of cfree and cbound. The ratio of cfree and φ is the 
unbound fraction and is denoted by εfree. 
 Plasma protein bound fraction can also be defined as εbound = 1 – εfree. 
 Information about the level of protein binding of the drug in serum is obtained from studies 
in vitro as parameters such as the association constant (Ka), the plasma protein binding (PPB) or the 
unbound fraction fuP (2). 
 Recently, a number of papers appeared which criticize application of the unbound fraction 
determined in vitro to PK parameters calculation in clinical practice (3). 
 In our work we have derived a formula that allows to calculate the free drug concentration at 
any time after the drug application, based on 3 parameters: the association constant of the drug, the 
total plasma concentration of the drug and the concentration of the protein. The model has been 
constructed under Goldberg-Waage law of mass action (4). 
 
 
 
Assumption and basic equations 
 
 In our discussion we assume a single intravenous dose application, determination of the total 
drug concentration in blood serum within the limit of detection in time intervals from t0 to ti, and 
determination of the total protein concentration. In the calculations we also use the association 
constant (Ka) of the drug. It`s inverse, the dissociation constant Kd is a binding parameter (5). 
 Let us consider the case when the drug is eliminated, but the total amount of plasma protein 
is conserved (in vivo). The total amount of the protein (λ) is the sum of the protein bound with the 
drug (cbound,i) and the free form of the protein (ei). 
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From (1) the following is obtained: 
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As is well known, the law of mass action has the form: 
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After inserting (2) into (3) one obtains: 
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And therefore: 
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New approach 
 
 The sum of both forms of a drug g (cbound,i + cfree,i) must be equal to the total concentration of 
the drug, which will be denoted by φi: 
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Equation (6) implies the relation: 
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which is a trinomial square of cfree,i with parameters Ka, Λ and φi. 
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 Cbound,i can be obtained by inserting (8) into (5). Afterwards, the percentage of free and 
bound with protein forms of the drug (εfree and εbound) can be calculated at any time after i.v. 
application of a single drug dose. 
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And for unbound fraction: 
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 It should be emphasized that both bound fractions are now the functions of the variables Ka, 
Λ and φi. 
 For small values of φi: 
φi ≈ 0          (11) 
the two last relations simplify to: 
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 It is worth to note that assuming the (11) limitation the sum of (12) and (13) is equal to 1 
which indirectly proves the correctness of the calculations. 
 
 
 
Disscussion 
 
 The proposed formula enables calculation of the free drug concentration and the unbound 
fraction of a drug at any time after a single intravenous dose is applied. 
An important advantage of this method of calculating cfree and fuP in vivo is satisfying Goldberg 
Waage law at any point of time after the drug application when quantitative determination of the 
total drug concentration is feasible. 
 The absence of the elimination rate constant in the formula is not an error because the 
parameter is hidden in the values of the total drug concentrations. 
 It is essential that the association constant (Ka) determined in vitro and the total amount of 
the drug (Λ) and the total drug concentration (ctotal) are all obtained from the same serum. 
 This means that described procedure could be used in the phase of gathering information 
about the pharmacokinetic properties of the drug in both preclinical studies and clinical trials in 
phase I and II.  
  It seems that our observations provide an important complement to existing methods 
of analysis to pharmacokinetics processes. 
We expect to verify the proposed model in further research on experimental data. 
 
 
 
 
 
  
 
 
 
REFERENCES 
 
1.Toutain P. I., Bousquet-Melou A. (2002) Free drug fraction vs. free drug concentration: a matter 
of frequent confusion. J. Vet. Pharmacol. Therap. 25, 460–463. 
2.Schmidt S., Gonzalez D., Derendorf H. (2010) Significance of protein binding in 
pharmacokinetics and pharmacodynamics Journal of Pharmaceutical Sciences Volume 99, Issue 3, 
pages 1107–1122, March 2010. 
3.Smith D. A., Li Di., Kerns E. H. (2010) The effect of plasma protein binding on in vivo efficacy: 
misconceptions in drug discovery Nature Reviews Drug Discovery 9, 929-939 (December 2010) | 
doi:10.1038/nrd3287). 
4.Waage, P. Guldberg, C. M. (1834) Forhandlinger: Videnskabs-Selskabet i Christiana, 35. 
expression (8). 
